Does acid suppression by antacids and H2 receptor antagonists increase the incidence of atrophic gastritis in patients with or without H-pylori gastritis?

被引:6
作者
Carter, M
Katz, DL
Haque, S
Deluca, VA
机构
[1] Griffin Hosp, Gastroenterol Sect, Derby, CT 06418 USA
[2] Griffin Hosp, Sect Prevent Med, Derby, CT 06418 USA
[3] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA
[4] Yale Univ, Sch Med, Dept Epidemiol, New Haven, CT 06510 USA
[5] Tulane Univ, Sch Med, New Orleans, LA 70112 USA
关键词
acid suppression; antacids; H; pylori; astrophic gastritis; H2 receptor antagonists;
D O I
10.1097/00004836-199909000-00016
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Currently there is controversial evidence that suggests that the accepted incidence of atrophic gastritis of 1.2 to 3.3% in patients with Helicobacter pylori gastritis may be increased by the long-term suppression of acid by a proton pump inhibitor (omeprazole). The purpose of this study is to show whether lesser forms of acid suppression by antacids or H2 receptor antagonists may have an influence on the development of atrophic gastritis. The authors recently reported a study in which a cohort of 36 patients with symptoms of dyspepsia were followed clinically for a period of 7 to 19 years. In that report all subjects underwent upper endoscopy with two biopsy specimens each from the antrum and fundus, on at least two occasions, 7 to 19 years apart. A diagnosis of atrophic gastritis was based on the interpretation of these biopsies by two gastrointestinal pathologists. The presence of H. pylori colonization was determined by tissue sampling and by a campylobacter-like organisms test of the antrum. Of the 36 patients in the authors' previous report, 33 had adequate baseline and follow-up data on medications consumed throughout the period of the study. In their current report they now present the findings of a retrospective review in which they correlate the presence of atrophic gastritis with the sole use of antacids and H2 receptor antagonists throughout the period of the study. In the cohort of 33 patients evaluated from the previous report, the authors found that atrophic,gastritis had developed in all 28 patients positive for H, pylori, and in none of the 5 patients negative for H. pylori (p < 0.0001). A retrospective analysis of this previously studied cohort of 33 patients revealed that the use of antacids and H2 receptor antagonists did not predict the development of atrophic gastritis in either H. pylori-negative or -positive subjects. In a retrospective analysis of a cohort of 33 patients followed for an average of 11.7 years, atrophic gastritis developed in H, pylori-positive but not in H. pylori-negative subjects, irrespective of the use and duration of antacids or H2 receptor antagonists.
引用
收藏
页码:183 / 187
页数:5
相关论文
共 11 条
[1]   Long-term symptom patterns, endoscopic findings, and gastric histology in Helicobacter pylori-infected and -uninfected patients [J].
DeLuca, VA ;
West, AB ;
Haque, S ;
Katz, DL ;
Ciarolla, D ;
Goldenberg, S ;
Fette, G .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 1998, 26 (02) :106-112
[2]   Classification and grading of gastritis - The updated Sydney System [J].
Dixon, MF ;
Genta, RM ;
Yardley, JH ;
Correa, P ;
Batts, KP ;
Dahms, BB ;
Filipe, MI ;
Haggitt, RC ;
Haot, J ;
Hui, PK ;
Lechago, J ;
Lewin, K ;
Offerhaus, JA ;
Price, AB ;
Riddell, RH ;
Sipponen, P ;
Solcia, E ;
Watanabe, H .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) :1161-1181
[3]   Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia [J].
Eissele, R ;
Brunner, G ;
Simon, B ;
Solcia, E ;
Arnold, R .
GASTROENTEROLOGY, 1997, 112 (03) :707-717
[4]  
HAQUE S, 1992, GASTROENTEROLOGY, V102, pA79
[5]  
IHAMAKI T, 1978, SCAND J GASTROENTERO, V13, P1771
[6]  
KIUPERS EJ, 1996, NEW ENGL J MED, V334, P1018
[7]   LONG-TERM SEQUELAE OF HELICOBACTER-PYLORI GASTRITIS [J].
KUIPERS, EJ ;
UYTERLINDE, AM ;
PENA, AS ;
ROOSENDAAL, R ;
PALS, G ;
NELIS, GF ;
FESTEN, HPM ;
MEUWISSEN, SGM .
LANCET, 1995, 345 (8964) :1525-1528
[8]   LONG-TERM OMEPRAZOLE THERAPY IN PEPTIC-ULCER DISEASE - GASTRIN, ENDOCRINE CELL-GROWTH, AND GASTRITIS [J].
LAMBERTS, R ;
CREUTZFELDT, W ;
STRUBER, HG ;
BRUNNER, G ;
SOLCIA, E .
GASTROENTEROLOGY, 1993, 104 (05) :1356-1370
[9]  
Lundell L, 1997, GASTROENTEROLOGY, V112, pA28
[10]  
*SAS I INC, 1989, SAS STAT US GUID VER, P875